Updated:
aMoon
aMoon partners with exceptional scientists and entrepreneurs to build great companies and accelerate cure. Through aMoon Velocity and aMoon Growth, the firm...
Overview
aMoon partners with exceptional scientists and entrepreneurs to build great companies and accelerate cure. Through aMoon Velocity and aMoon Growth, the firm invests in early and late-stage companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. It builds bridges between portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality.
General information
Firm type
Private Equity
Year founded
2016
Location
Region
Middle East
Country
Israel
City
Raanana
Corporate office
Ra'anana, Israel
Principals
Yair Schindel
MD, MBA — Co-Founder & Managing Partner
Tomer Berkovitz
PhD — Managing Partner
Todd Sone
MBA — General Partner
Moshic Mor
MBA — General Partner
Yaron Daniely
PhD, MBA — General Partner & Head of aMoon Alpha
Reut Shema
PhD — Partner
Roy Wiesner
Adv., MPA — Partner
Patrick Rivers
MBA — Portfolio Manager
Tamir Maixner
MBA — Principal
Adam Kotzen — Principal
Hagai Marmor-Kollet
PhD — Associate
Rey Mozer
MD, MBA — Associate
Daniel Sass
MD, MBA — Associate
David Esra
MD — Analyst
Sharon Feldman
PhD — Analyst
Shachar Elias — Intern
Irena Katsman
CPA, MBA — Chief Financial Officer
Noam Waldoks
JD — Chief Legal Officer
Osnat Tirosh — Chief People Officer & Chief of Staff
Noah Lasson
JD, MBA — Chief Compliance Officer & CISO
Gaby Hirsch — VP Investor Relations
Yodfat Melzer
CPA, MBA — VP Finance
David Dubinsky
CPA — Controller
Isaac Devash — Venture Partner
Samuel Moed — Venture Partner
Sector focus
Frequently asked questions
What investment stages does aMoon target?
aMoon operates across the full HealthTech lifecycle. The firm's venture strategy covers early-stage, seed, and startup investments, while its growth equity vehicles target expansion and late-stage companies. This structure is designed to provide continuity of capital from initial product development through commercial scaling.
Is aMoon a generalist venture firm or sector-specific?
aMoon is a pure-play HealthTech investor. The firm does not diversify into enterprise software, fintech, consumer internet, or other technology verticals. Its entire mandate is concentrated within healthcare services, digital health, and life sciences ventures emerging primarily from Israel's innovation ecosystem.
Does aMoon invest exclusively in Israel?
aMoon's headquarters are in Ra'anana, and the firm's core sourcing model is anchored in Israel's academic and medical research institutions. While the firm targets companies with global regulatory strategies and international commercial ambitions, detailed geographic allocation data is not disclosed.
How is aMoon structured as an asset manager?
aMoon functions as a multi-fund private equity manager. It operates separate early-stage venture vehicles alongside dedicated growth equity funds. This dual-fund architecture distinguishes it from single-fund health VCs and from large generalist growth platforms that treat healthcare as one of many sectors.
Does aMoon participate in fund commitments or only direct deals?
Available information describes aMoon as a direct investor in private companies across venture and growth stages. There is no public disclosure of a fund-of-funds program or limited partner commitments to external PE or VC managers.
Does aMoon disclose its assets under management?
No. aMoon does not publish an AUM figure, and no specific number has appeared in regulatory filings or media reports accessible for this review. The firm's financial scale is not publicly verifiable.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: